Avaí Bio, Inc. (OTCQB: AVAI) and its joint venture partner Austrianova have announced the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the alpha-Klotho protein, a key step toward clinical trials for an anti-aging therapy.
Master Cell Bank Milestone
The MCB, announced on May 20, 2026, will undergo comprehensive independent testing by a top-tier, accredited third-party provider to confirm the absence of pathogenic viruses and adventitious agents such as bacteria, mycoplasma, fungi and yeast, in line with regulatory expectations including those of the FDA.
Following successful testing, the next step is a Working Cell Bank (WCB) derived from the MCB, which will be used to manufacture the final Cell-in-a-Box encapsulated clinical product. This milestone falls under the September 2025 joint venture Klothonova, a Nevada-based company equally owned by Avaí Bio and Austrianova’s affiliate SG Austria Pte. Ltd.
Alpha-Klotho and Aging Biology
Alpha-Klotho is a circulating regulatory protein whose age-related decline has been linked in published research to kidney disease, neurodegenerative disorders and vascular disease. Its restoration is one of the most actively studied questions in aging biology.
According to Avaí Bio, the MCB is a major step on the company's path to clinical trials, as cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging.
Broader Cell Therapy Landscape
Across the broader cell-therapy landscape, developers are posting milestones. Sana Biotechnology (NASDAQ: SANA) reported 14-month insulin independence data in Type 1 diabetes without immunosuppression. Eledon Pharmaceuticals (NASDAQ: ELDN) saw all evaluable patients reach insulin independence in an islet-transplant trial pairing tegoprubart with donor islets.
NewcelX Ltd. (NASDAQ: NCEL) submitted its pre-IND package to the FDA for a stem-cell-derived islet therapy. Vertex Pharmaceuticals (NASDAQ: VRTX) reported that all 12 patients in the Phase 1/2 portion of its stem-cell-derived islet therapy trial restored insulin production, though it has temporarily postponed completion of dosing pending an internal manufacturing analysis.
Avaí Bio's Strategic Position
Avaí Bio is an emerging biotechnology company developing cell-based therapies for diabetes, age-related disorders and anti-aging. Its strategic anchor is Klothonova, its joint venture with Austrianova, a Singapore-based biotechnology company specializing in cell encapsulation, GMP-grade cell products and cell line development, backed by more than 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.
